[Form 4] Idexx Laboratories Inc Insider Trading Activity

Rhea-AI Filing Summary

Idexx Laboratories executive Nimrata Hunt reported option exercises and market sales on 08/06/2025. The filing shows conversion of non-qualified stock options into common stock for 1,218, 5,865 and 5,711 shares at strikes of $141.60, $178.26 and $206.94 respectively, and three open-market sales totaling 7,143 shares at prices between $630.6891 and $630.9087. The reporting person owned 25,149.9435 shares before the sales and owned 18,006.9435 shares directly after the transactions, with an additional 160 shares held indirectly (jointly with spouse). The Form documents the mechanics of option-to-share conversion and subsequent sales without stating motives.

Positive

• Converted vested options to common stock for 1,218, 5,865 and 5,711 shares at strike prices of $141.60, $178.26 and $206.94 respectively.
• Maintains direct ownership of 18,006.9435 shares after transactions and 160 shares indirectly (jointly with spouse), indicating retained equity stake.

Negative

• Sold 7,143 shares on 08/06/2025 at prices ranging from $630.6891 to $630.9087, reducing direct holdings from 25,149.9435 to 18,006.9435 shares.
• Filing does not state the reason for the sales or intended use of proceeds; motives are not disclosed in the Form.

Insights

Financial Analyst

TL;DR: Executive exercised previously granted options at low strike prices and sold a portion of resulting shares at ~ $631 each; remaining direct holding ~18,006.94 shares.

The filing documents exercises of three option tranches (1,218 at $141.60; 5,865 at $178.26; 5,711 at $206.94) and subsequent market sales of 7,143 shares at prices between $630.6891 and $630.9087 on 08/06/2025. These transactions reduced direct beneficial ownership from 25,149.9435 to 18,006.9435 shares while leaving 160 shares held indirectly. From a market-impact perspective the filing shows routine compensation-related activity rather than a corporate event; the scales of exercise and sale are explicit but the Form does not state intended uses of proceeds or reasons for sales.

Corporate Governance Expert

TL;DR: The Form 4 reflects standard option exercise and disclosure-compliant sales by a senior officer, with continued ownership retained post-transactions.

The report is consistent with typical executive equity-plan activity: vested option tranches converted into common stock and then partial disposition via three sales. The filing specifies ownership totals before and after the transactions and notes 160 shares held jointly with a spouse. The document contains no indication of policy or governance issues, nor any explicit insider trading plan detail beyond the transactions themselves.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hunt Nimrata

(Last) (First) (Middle)

ONE IDEXX DRIVE

(Street)

WESTBROOK ME 04092

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
IDEXX LABORATORIES INC /DE [ IDXX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Executive Vice President

3. Date of Earliest Transaction (Month/Day/Year)
08/06/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/06/2025		M		1,218	A	$141.6	13,573.9435(1)	D
Common Stock	08/06/2025		M		5,865	A	$178.26	19,438.9435	D
Common Stock	08/06/2025		M		5,711	A	$206.94	25,149.9435	D
Common Stock	08/06/2025		S		3,018	D	$629.865	22,131.9435	D
Common Stock	08/06/2025		S		2,907	D	$630.9087(2)	19,224.9435	D
Common Stock	08/06/2025		S		1,218	D	$630.6891	18,006.9435	D
Common Stock								160	I	jointly with spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-Qualified Stock Option (right-to-buy)	$141.6	08/06/2025		M			1,218	(3)	02/13/2027	Common Stock	1,218	$0	0	D
Non-Qualified Stock Option (right-to-buy)	$178.26	08/06/2025		M			5,865	(4)	02/13/2028	Common Stock	5,865	$0	0	D
Non-Qualified Stock Option (right-to-buy)	$206.94	08/06/2025		M			5,711	(5)	02/13/2029	Common Stock	5,711	$0	0	D

Explanation of Responses:

1. Includes a total of 28.7090 shares purchased under the Issuer Employee Stock Purchase Plan on March 31, 2025 and June 30, 2025.

2. Represents the weighted average price of the shares sold ranging from a low of $630.50 to a high of $630.94 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

3. Grant of option to buy shares of Issuer common stock that became exercisable in five annual installments beginning February 14, 2018.

4. Grant of option to buy shares of Issuer common stock that became exercisable in five annual installments beginning February 14, 2019.

5. Grant of option to buy shares of Issuer common stock that became exercisable in five annual installments beginning February 14, 2020.

Remarks:

	/s/ Lily J. Lu, Attorney-in-Fact for Nimrata Hunt	08/08/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transactions did Nimrata Hunt report on the IDXX Form 4?

The filing reports exercises of non-qualified stock options for 1,218, 5,865 and 5,711 shares (strikes $141.60, $178.26, $206.94) and three market sales totaling 7,143 shares.

How many shares were sold and at what prices in the IDXX filing?

Three sales totaling 7,143 shares occurred at prices between $630.6891 and $630.9087, with a reported weighted-average range noted in the filing.

How many options were exercised and what were the strike prices?

Options converting to common stock were for 1,218 shares at $141.60, 5,865 shares at $178.26, and 5,711 shares at $206.94.

What is Nimrata Hunt's beneficial ownership after these transactions?

After the reported transactions the filing shows 18,006.9435 shares direct and 160 shares indirect (jointly with spouse).

Are any derivative securities reported as remaining after the transactions?

The Form indicates the exercised option tranches and shows 0 derivative securities beneficially owned following the reported transactions as presented in Table II.

Who signed the Form 4 on behalf of the reporting person?

The Form is signed by Lily J. Lu, Attorney‑in‑Fact for Nimrata Hunt as the reporting person’s representative.